Articles Related to Carboplatin
Compliance in the Duration of Administration of Anticancer Chemotherapy: Comparative Study of Two Different Administration Modalities (PVC versus IVAD)
Objective: To evaluate the compliance of chemotherapy administration duration by comparing the peripheral venous catheter (PVC) route with the implantable venous access device (IVAD).Keywords: Chemotherapy; Gravity perfusion; Peripheral venous; Implantable venous access deviceIntroduction Methods: This was a retrospective study that analyzed 566 cycles of chemotherapy administered by PVC at the Cancer Unit of Yalgado Ouédraogo University Hospital and 258 cycles administered by IVAD at the Oncology Department of Treichville University Hospital in Abidjan. We compared the differences between the programmed duration of chemotherapy and the actual duration of administration according to the two routes of administration.
Carcinoma of unknown primary site (CUP) is a heterogeneous group of malignancies associated with dismal prognosis. Although majority of the patients present with disseminated disease, some of them do present with disease limited to the lymph nodes.
Overuse and Misuse of Adjuvant Chemotherapy for Stages I and II Non-Small Cell Lung Cancer Chemotherapy: Empirical Findings from a Privately Insured Population
Among persons with early stage non-small cell lung cancer (NSCLC) resected for cure, appropriate use of adjuvant chemotherapy is an important additional determinant of survival. Oncology quality improvement initiatives focus on reducing overuse, underuse, and misuse.
The high mortality associated with ovarian cancer is generally related to the development of drug-resistant disease. HMGA2 protein, a member of the high-mobility group AT-hook (HMGA) family of non-histone chromatin binding factors, is overexpressed in high-grade serous ovarian and tubal carcinomas, though little is known about its contribution to disease progression and drug resistance. We sought to assess whether compositional changes in HMGA2 production were associated with ovarian cancer progression.
Development of Severe Hypophosphatemia from Acquired Fanconi Syndrome during Treatment with Abiraterone
The first patient was a 77 year old man who had been on abiraterone for 12 months before his phosphorous was checked. At that point, it was 0.6 mg/dl, which is severely decreased. A full work up for hypophosphatemia showed normal parathyroid hormone and 25-hydroxyvitamin D. A urine study showed inappropriate excretion of phosphorous along with aminoaciduria and normoglycemic glucosuria.
Cancer is a highly heterogeneous disease characterised by continuous uncontrolled growth and expansion of abnormal cells. In general, in tumor cells the signalling pathways regulating cellular processes, as cell growth and division and cell to cellcommunication result strongly altered.